EN DE
Watch EVE Health Group Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

EVE Health Group Limited (EVE) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of EVE Health Group Limited stock A$0.01, price A$0.01, upside +4.5%, quality 54 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive AU · ISIN AU000000EVE3

EH EVE Health Group Limited logo Thin data Nov 10, 2026

EVE Health Group Limited

EVE · AU
Fairly valued, in a downtrend

The stock costs about what our calculation considers fair.

Low debt
Fair value A$0.0136 · Fairly valued
Quality 54/100
Revenue last quarter 37% below a year ago.
Weak Growth (revenue 5y −5.6 %/yr in AUD)
Loss-making · -119.1% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 9/100 · thin data
Thin data
Estimate
Watch EVE Health Group Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.2000 A$0.0110 Fair Value A$0.0136 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0110 – A$0.2000 · fair‑value band A$0.0132 – A$0.0140 · the A$0.0130 price screens below the A$0.0136 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow EVE Health Group in your weekly email

Every Wednesday you see whether EVE Health Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products.

Show moreShow less

The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction.

It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.

Stock analysis

EVE Health Group Limited (EVE) currently trades at A$0.0130, while our estimate is A$0.0136, so the stock looks roughly fairly valued today (gap 4.3%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0132 (bear) to A$0.0140 (bull), the price of A$0.0130 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Consumer Defensive sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

EVE Health Group Limited reported revenue of A$1.7M in FY2025 versus A$2.8M in FY2021, a compound −11.3%/yr. Reported net income was −A$1.6M in FY2025.

Key figures

Market cap A$4.6M (≈ $3.2M) Micro · P/S ratio 4.40 · EPS (TTM) A$−0.0100 · Net margin −91.1% · Return on equity −77.7% · Return on assets (EBIT) −46.3% (5-year average) · Operating margin −135% · Revenue (TTM) A$1.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 58% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 2% fair-value upside, at 4%, EVE screens cheaper than that median.

Fair Value

Bear A$0.0132 Fair Value A$0.0136 Bull A$0.0140
Price A$0.0130 · Upside +4.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 34
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−18.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.6%
Start year 2020 (pandemic). Over 10 years: +147.9% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−113.2% (2020) → −82.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch EVE, get fair value alerts →

Compare EVE Health Group Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 660 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside +4.6% · Above median
Profitability
Return on assets −38.3% · Bottom 25%
Net margin (12 months) −119.1% · Bottom 25%
Operating margin (12 months) −134.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −37.1% · Bottom 25%

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B 1.29× · Cheaper than median
P/S (12 months) 3.37× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 34
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 30
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 55

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 2.95 SGD 4.93 SGD +67% vs EVE
Inner Mongolia Yili Industrial Group 600887 ¥31.14 ¥41.84 +34% vs EVE
The Kraft Heinz Company KHC $24.24 $29.20 +20% vs EVE
Foshan Haitian Flavouring and Food Company 603288 ¥35.46 ¥39.22 +11% vs EVE
General Mills, Inc GIS $34.60 $35.30 +2% vs EVE
Danone S.A BN €68.32 €50.65 −26% vs EVE
Nestlé S.A NESN CHF 86.41 CHF 59.51 −31% vs EVE
Kerry Group KRZ €97.10 €60.33 −38% vs EVE
Nestlé India Limited NESTLEIND ₹1,298 ₹724.74 −44% vs EVE
Yihai Kerry Arawana Holdings 300999 ¥25.92 ¥12.21 −53% vs EVE

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

EVE Health Group Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "EVE Health Group Limited Fair Value". https://www.fairvalue-calculator.com/stock/EVE

Frequently asked questions

Is EVE Health Group Limited (EVE) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0136 versus a price of A$0.0130, about +4% upside (fairly valued).
What is the fair value of EVE?
Our estimate for EVE Health Group Limited is A$0.0136 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0130.
What is the quality score of EVE?
EVE Health Group Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EVE Health Group Limited (EVE)?
Our calculated price target is the estimate of A$0.0136 (as of Nov 10, 2026). Cautious scenario A$0.0132, optimistic scenario A$0.0140. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the EVE Health Group Limited stock forecast for 2026?
Our estimate puts fair value at A$0.0136, about +4% upside versus a price of A$0.0130 (fairly valued). Cautious scenario A$0.0132, optimistic scenario A$0.0140. The calculation is refreshed regularly with new filings.
What is the revenue of EVE Health Group Limited (EVE)?
EVE Health Group Limited reported trailing-twelve-month revenue of about A$1.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of EVE Health Group Limited (EVE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EVE Health Group Limited it is A$0.0136 per share (as of Nov 10, 2026), against a price of A$0.0130.
Is EVE Health Group Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, EVE trades below its calculated fair value: price A$0.0130, fair value A$0.0136, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVE?
No. The price is what the market pays today (A$0.0130); the fair value is what the company's own numbers justify (A$0.0136). For EVE Health Group Limited the two are A$0.0006 per share apart. That gap is exactly why we show both numbers side by side.
How much is EVE Health Group Limited worth?
The market values EVE Health Group Limited at about A$4.6M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0130; our models calculate a fair value of A$0.0136 per share.
What do the bullish and bearish scenarios say about EVE?
Our models span a range for EVE Health Group Limited: cautious scenario A$0.0132, base A$0.0136, optimistic A$0.0140 per share (as of Nov 10, 2026, price A$0.0130). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EVE Health Group Limited (EVE)?
Balance-sheet figures for EVE Health Group Limited (as of Nov 10, 2026): return on equity −77.7%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is EVE from its 52-week high?
EVE Health Group Limited trades at A$0.0130, about 58% below its 52-week high of A$0.0310 and 18% above the low of A$0.0110 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0136 is for.
Which stocks are comparable to EVE Health Group Limited?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EVE Health Group Limited stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0130, calculated fair value A$0.0136 (+4%), Quality Score 54/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. EVE Health Group Limited currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EVE Health Group Limited (EVE)?
The closing price on Nov 11, 2026 was A$0.0130. Our estimate is A$0.0136, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EVE Health Group Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (A$0.0132 to A$0.0140), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of EVE Health Group Limited

How large is the market capitalisation of EVE Health Group Limited (EVE)?
The market capitalisation of EVE Health Group Limited is A$4.6M (≈ $3.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EVE Health Group Limited (EVE)?
The price-to-sales ratio of EVE Health Group Limited is 4.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EVE Health Group Limited (EVE)?
Earnings per share at EVE Health Group Limited are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of EVE Health Group Limited (EVE)?
The net margin of EVE Health Group Limited is −91.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EVE Health Group Limited (EVE)?
The return on equity (ROE) of EVE Health Group Limited is −77.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EVE Health Group Limited (EVE)?
On an EBIT basis the return on assets of EVE Health Group Limited is −46.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EVE Health Group Limited (EVE)?
The operating margin of EVE Health Group Limited is −135% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EVE Health Group Limited (EVE)?
Revenue at EVE Health Group Limited is growing −37.1% versus a year earlier (3y avg −4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does EVE Health Group Limited (EVE) generate?
The free cash flow of EVE Health Group Limited is −A$1.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does EVE Health Group Limited (EVE) hold?
EVE Health Group Limited holds more cash than debt, A$812K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch EVE Health Group Limited in the live analysis

One click puts EVE Health Group Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.